The Rise of SARS-CoV-2 Variants and the Role of Convalescent Plasma Therapy for Management of Infections
Novel therapies for the treatment of COVID-19 are continuing to emerge as the SARSCov- 2 pandemic progresses. PCR remains the standard benchmark for initial diagnosis of COVID- 19 infection, while advances in immunological profiling are guiding clinical treatment. The SARSCov- 2 virus has undergo...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Published: |
MDPI
2021
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/20.500.12493/532 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Novel therapies for the treatment of COVID-19 are continuing to emerge as the SARSCov-
2 pandemic progresses. PCR remains the standard benchmark for initial diagnosis of COVID-
19 infection, while advances in immunological profiling are guiding clinical treatment. The SARSCov-
2 virus has undergone multiple mutations since its emergence in 2019, resulting in changes in
virulence that have impacted on disease severity globally. The emergence of more virulent variants
of SARS-Cov-2 remains challenging for effective disease control during this pandemic. Major variants
identified to date include B.1.1.7, B.1.351; P.1; B.1.617.2; B.1.427; P.2; P.3; B.1.525; and C.37.
Globally, large unvaccinated populations increase the risk of more and more variants arising. With
successive waves of COVID-19 emerging, strategies that mitigate against community transmission
need to be implemented, including increased vaccination coverage. For treatment, convalescent
plasma therapy, successfully deployed during recent Ebola outbreaks and for H1N1 influenza, can
increase survival rates and improve host responses to viral challenge. Convalescent plasma is rich
with cytokines (IL-1β, IL-2, IL-6, IL-17, and IL-8), CCL2, and TNFα, neutralizing antibodies, and
clotting factors essential for the management of SARS-CoV-2 infection. Clinical trials can inform and
guide treatment policy, leading to mainstream adoption of convalescent therapy. This review examines
the limited number of clinical trials published, to date that have deployed this therapy and
explores clinical trials in progress for the treatment of COVID-19. |
|---|